您当前所在的位置:首页 > 产品中心 > 产品详细信息
61337-87-9 分子结构
点击图片或这里关闭

5-methyl-2,5,19-triazatetracyclo[13.4.0.0^{2,7}.0^{8,13}]nonadeca-1(19),8(13),9,11,15,17-hexaene

ChemBase编号:254
分子式:C17H19N3
平均质量:265.35286
单一同位素质量:265.15789762
SMILES和InChIs

SMILES:
N12C(CN(CC1)C)c1c(Cc3c2nccc3)cccc1
Canonical SMILES:
CN1CCN2C(C1)c1ccccc1Cc1c2nccc1
InChI:
InChI=1S/C17H19N3/c1-19-9-10-20-16(12-19)15-7-3-2-5-13(15)11-14-6-4-8-18-17(14)20/h2-8,16H,9-12H2,1H3
InChIKey:
RONZAEMNMFQXRA-UHFFFAOYSA-N

引用这个纪录

CBID:254 http://www.chembase.cn/molecule-254.html

Collapse All Expand All

名称和登记号

名称和登记号

名称 登记号
IUPAC标准名
5-methyl-2,5,19-triazatetracyclo[13.4.0.0^{2,7}.0^{8,13}]nonadeca-1(19),8(13),9,11,15,17-hexaene
5-methyl-2,5,19-triazatetracyclo[13.4.0.0^{2,7}.0^{8,13}]nonadeca-1(15),8(13),9,11,16,18-hexaene
5-methyl-2,5,19-triazatetracyclo[13.4.0.02,7.08,13]nonadeca-1(15),8,10,12,16,18-hexaene
5-methyl-2,5,19-triazatetracyclo[13.4.0.02,7.08,13]nonadeca-1(15),8(13),9,11,16,18-hexaene
IUPAC传统名
5-methyl-2,5,19-triazatetracyclo[13.4.0.0^{2,7}.0^{8,13}]nonadeca-1(19),8(13),9,11,15,17-hexaene
5-methyl-2,5,19-triazatetracyclo[13.4.0.0^{2,7}.0^{8,13}]nonadeca-1(15),8(13),9,11,16,18-hexaene
mirtazapine
商标名
Remeron
Remeron Soltab
Zispin
Remergil
Norset
Rexer
Remergon
Mirtabene
Avanza
Mirtazon
Axit
Mirtaz
Promyrtil
Remeron, Avanza, Zispin
别名
Mirtazapina [INN-Spanish]
Mirtazapine [Usan:Ban:Inn]
Mirtazapinum [INN-Latin]
Mirtazepine
Mepirzepine
mirtazapine
Mirtazapine
Remeron
Avanza
Esmirtazapine
1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine
6-Azamianserin
Org 3770
Mirtazapine
5-methyl-2,5,19-triazatetracyclo[13.4.0.0^{2,7}.0^{8,13}]nonadeca-1(15),8(13),9,11,16,18-hexaene
Org-3770
Zispin
CAS号
61337-87-9
61337-67-5
85650-52-8
MDL号
MFCD00865427
PubChem SID
46506965
160963717
24724531
PubChem CID
6451144
4205
CHEBI ID
6950
ATC码
N06AX11
CHEMBL
654
Chemspider ID
4060
2342166
DrugBank ID
DB00370
KEGG ID
D04055
D00563
美国药典/FDA物质标识码
A051Q2099Q
4685R51V7M
维基百科标题
Esmirtazapine
Mirtazapine
Medline Plus
a697009

理论计算性质

理论计算性质

JChem ALOGPS 2.1
质子受体 质子供体
LogD (pH = 5.5) 1.8185004  LogD (pH = 7.4) 3.133914 
Log P 3.2079828  摩尔折射率 82.6553 cm3
极化性 31.225294 Å3 极化表面积 19.37 Å2
可自由旋转的化学键 里宾斯基五规则 true 
Log P 2.9  LOG S -2.38 
溶解度 1.10e+00 g/l 

分子性质

分子性质

理化性质 安全信息 药理学性质 产品相关信息 生物活性(PubChem)
溶解度
Chloroform expand 查看数据来源
DMSO: soluble ~8 mg/mL expand 查看数据来源
Slight expand 查看数据来源
Soluble in methanol and chloroform expand 查看数据来源
外观
white powder expand 查看数据来源
White Solid expand 查看数据来源
熔点
114-116 °C (237.2-240.8°F) expand 查看数据来源
114-116°C expand 查看数据来源
沸点
432°C (809.6°F) expand 查看数据来源
密度
1.22 g/cm3 expand 查看数据来源
疏水性(logP)
2.814 expand 查看数据来源
2.9 expand 查看数据来源
保存条件
-20°C expand 查看数据来源
-20°C Freezer expand 查看数据来源
MSDS下载
下载链接 expand 查看数据来源
下载链接 expand 查看数据来源
德国WGK号
3 expand 查看数据来源
个人保护装置
Eyeshields, Gloves, type N95 (US), type P1 (EN143) respirator filter expand 查看数据来源
给药途径
Oral expand 查看数据来源
生物利用度
50% expand 查看数据来源
排泄
Urine (75%)
Feces (15%)
expand 查看数据来源
半衰期
20–40 hours expand 查看数据来源
代谢
Liver (CYP1A2, CYP2D6, and CYP3A4) expand 查看数据来源
Liver (CYP2D6) expand 查看数据来源
蛋白结合率
85% expand 查看数据来源
法定药品分级
Rx-only expand 查看数据来源
Uncontrolled expand 查看数据来源
妊娠期药物分类
C expand 查看数据来源
相关基因信息
human ... ADRA2A(150), ADRA2C(152), DRD2(1813), DRD3(1814), DRD4(1815), HRH1(3269), HTR1A(3350), HTR2A(3356), HTR2C(3358), HTR7(3363)mouse ... Slc6a2(20538)rat ... Adra1a(29412), Drd1a(24316), Drd2(24318), Htr1a(24473), Htr2a(29595), Htr2c(25187), Slc6a3(24898), Slc6a4(25553) expand 查看数据来源
纯度
≥98% (HPLC) expand 查看数据来源
95% expand 查看数据来源
成盐信息
Free Base expand 查看数据来源
质检报告
下载链接 expand 查看数据来源
Empirical Formula (Hill Notation)
C17H19N3 expand 查看数据来源

详细说明

详细说明

Selleck Chemicals Selleck Chemicals Sigma Aldrich Sigma Aldrich TRC TRC Wikipedia Wikipedia DrugBank DrugBank
Selleck Chemicals -  S2016 external link
Research Area: Neurological Disease
Biological Activity:
Mirtazapine (Remeron, Avanza) is a potent tetracyclic antidepressant. Mirtazapine (Remeron, Avanza) used primarily in the treatment of depression. It is also sometimes used as a hypnotic, antiemetic, and appetite stimulant, and for the treatment of anxiety, among other indications. In addition, along with its close analogues mianserin and setiptiline, mirtazapine (Remeron, Avanza) is one of the few noradrenergic and specific serotonergic antidepressants (NaSSAs). Additionally, the (S)-(+)-enantiomer of mirtazapine, which is also called esmirtazapine, is currently under development for the treatment of insomnia and menopausal symptoms. Mirtazapine’s primary use is the treatment of major depressive disorder. Mirtazapine (Remeron, Avanza) has been found to be useful in the treatment of many diseases, including generalized anxiety disorder, social anxiety disorder, obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder, seasonal affective disorder, insomnia, nausea and vomiting, diminished appetite and associated weight loss, and itching as well. [1]References on Mirtazapine (Remeron, Avanza)[1] http://en.wikipedia.org/wiki/Mirtazapine, ,
Sigma Aldrich -  M0443 external link
Biochem/physiol Actions
Mirtazapine is a noradrenergic and specific serotonergic antidepressant (NaSSA). Mirtazapine agonizes selective adrenergic and serotonergic receptors so that both NE release and 5-HT1A mediated serotonergic signaling are increased.
Toronto Research Chemicals -  M365000 external link
An α2-Adrenergic blocker; analogue of Mianserin. Antidepressant.
DrugBank -  DB00370 external link
Item Information
Drug Groups approved
Description Mirtazapine is an antidepressant introduced by Organon International in 1996 used for the treatment of moderate to severe depression. Mirtazapine has a tetracyclic chemical structure and is classified as a noradrenergic and specific serotonergic antidepressant (NaSSA). It is the only tetracyclic antidepressant that has been approved by the Food and Drug Administration to treat depression. [Wikipedia]
Indication For the treatment of major depressive disorder.
Pharmacology Mirtazapine, an antidepressant of the piperazinoazepine class, is a tetracyclic compound with an anxiolytic effect. Mirtazapine has fewer ADRs than tricyclic antidepressants and is better tolerated. Selective blockade of specific serotonin receptors by mirtazapine likey minimizes side effects typical of other antidepressants.
Toxicity Symptoms of overdose include disorientation, drowsiness, impaired memory, and tachycardia. LD50 is 600-720mg/kg (oral, mice) and 320-490mg/kg (oral, rat) [PMID: 10333982]
Affected Organisms
Humans and other mammals
Biotransformation Mirtazapine is extensively metabolized by demethylation and hydroxylation followed by glucuronide conjugation. Cytochrome P450 2D6 and cytochrome P450 1A2 are involved in formation of the 8-hydroxy metabolite of mirtazapine, and cytochrome P450 3A4 is responsible for the formation of the N-desmethyl and N-oxide metabolites. Several metabolites possess pharmacological activity, but plasma levels are very low.
Absorption Rapid and complete, but, due to first-pass metabolism, absolute bioavailability is 50%.
Half Life 20-40 hours
Protein Binding 85%
Elimination This drug is known to be substantially excreted by the kidney (75%).
References
Gillman PK: A systematic review of the serotonergic effects of mirtazapine in humans: implications for its dual action status. Hum Psychopharmacol. 2006 Mar;21(2):117-25. [Pubmed]
Burrows GD, Kremer CM: Mirtazapine: clinical advantages in the treatment of depression. J Clin Psychopharmacol. 1997 Apr;17 Suppl 1:34S-39S. [Pubmed]
Velazquez C, Carlson A, Stokes KA, Leikin JB: Relative safety of mirtazapine overdose. Vet Hum Toxicol. 2001 Dec;43(6):342-4. [Pubmed]
Gorman JM: Mirtazapine: clinical overview. J Clin Psychiatry. 1999;60 Suppl 17:9-13; discussion 46-8. [Pubmed]
Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, Bond A, Davidson JR, den Boer JA, Fineberg NA, Knapp M, Scott J, Wittchen HU: Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2005 Nov;19(6):567-96. [Pubmed]
[Pubmed]
External Links
Wikipedia
RxList
PDRhealth
Drugs.com

参考文献

参考文献

供应商提供 Google Scholar IconGoogle Scholar PubMed iconPubMed Google Books IconGoogle Books
  • De Boer, T., et al.: Neuropharmacology, 27, 399 (1988)
  • Smith, W.T., et al.: Psychopharmacol. Bull., 26, 191 (1990)
  • Gorman JM: Mirtazapine: clinical overview. J Clin Psychiatry. 1999;60 Suppl 17:9-13; discussion 46-8. Pubmed
  • Pubmed
  • Gillman PK: A systematic review of the serotonergic effects of mirtazapine in humans: implications for its dual action status. Hum Psychopharmacol. 2006 Mar;21(2):117-25. Pubmed
  • Burrows GD, Kremer CM: Mirtazapine: clinical advantages in the treatment of depression. J Clin Psychopharmacol. 1997 Apr;17 Suppl 1:34S-39S. Pubmed
  • Velazquez C, Carlson A, Stokes KA, Leikin JB: Relative safety of mirtazapine overdose. Vet Hum Toxicol. 2001 Dec;43(6):342-4. Pubmed
  • Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, Bond A, Davidson JR, den Boer JA, Fineberg NA, Knapp M, Scott J, Wittchen HU: Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2005 Nov;19(6):567-96. Pubmed
  • http://en.wikipedia.org/wiki/Mirtazapine
正在搜索,请耐心等待...(如果遇到网页错误或者长时间没有结果,请刷新页面[F5])

专利

专利

PubChem iconPubChem Patent Google Patent Search IconGoogle Patent

互联网资源

互联网资源

百度图标百度 google iconGoogle